Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 122

Results For "ARI"

3851 News Found

Biocon Biologics receives Health Canada approval for Yesafili
Drug Approval | June 27, 2025

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data


Philogen withdraws marketing authorization application for Nidlegy in EU
News | June 26, 2025

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls


Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Biotech | June 26, 2025

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability


Ashland expands viatel bioresorbable polymers offering for medical devices
Medical Device | June 26, 2025

Ashland expands viatel bioresorbable polymers offering for medical devices

Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants


Glenmark Pharmaceuticals launches TEVIMBRA in India
News | June 25, 2025

Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)


Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing
Healthcare | June 24, 2025

Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing

This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey


Biocon Biologics collaborates with National Cancer Society Malaysia
Healthcare | June 24, 2025

Biocon Biologics collaborates with National Cancer Society Malaysia

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints


Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH
Clinical Trials | June 24, 2025

Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH

WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy


Emcure to acquire remaining stake in Zuventus Healthcare
News | June 23, 2025

Emcure to acquire remaining stake in Zuventus Healthcare

The transaction is expected to close in Q2 FY 2026